10.50
-0.14 (-1.32%)
| Previous Close | 10.64 |
| Open | 10.50 |
| Volume | 1,571,165 |
| Avg. Volume (3M) | 2,718,011 |
| Market Cap | 733,048,000 |
| Price / Sales | 7.91 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Phathom Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ensign Peak Advisors, Inc | 31 Mar 2025 | 2,514,284 |
| Catalys Pacific, Llc | 31 Mar 2025 | 1,167,114 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Needham, 166.67%) | Buy |
| Median | 17.00 (61.91%) | |
| Low | 5.00 (Goldman Sachs, -52.38%) | Hold |
| Average | 16.40 (56.19%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 6.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 09 Jun 2025 | 17.00 (61.90%) | Buy | 8.83 |
| HC Wainwright & Co. | 09 Jun 2025 | 20.00 (90.48%) | Buy | 8.83 |
| 02 May 2025 | 20.00 (90.48%) | Buy | 2.76 | |
| Needham | 06 Jun 2025 | 28.00 (166.67%) | Buy | 8.92 |
| 21 Apr 2025 | 28.00 (166.67%) | Buy | 3.90 | |
| Goldman Sachs | 02 May 2025 | 5.00 (-52.38%) | Hold | 2.76 |
| 17 Apr 2025 | 10.00 (-4.76%) | Hold | 4.03 | |
| Guggenheim | 02 May 2025 | 12.00 (14.29%) | Buy | 2.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |